NSE: GLENMARK | BSE: 532296

Strong Performer, Getting Expensive

Download real time

2219.20 38.10 (1.75%)

High vol.+gain this week

NSE 14 Jul, 2025 3:58 PM (IST)

62,626

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Analyst Buy

Motilal Oswal retains 'Buy' call on Glenmark Pharma, expects a revenue CAGR of 10.6% over FY26-27 See details

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2219.20

1.75%

Stock Flash

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of Glenmark
Pharmaceuticals, has entered into an exclusive global licensing agreement
with AbbVie for the development and commercialization of IGI’s lead
oncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecific
antibody is currently in Phase 1 clinical trials for relapsed/refractory multiple
myeloma (R/R MM).

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2219.20

1.75%

Innovation validated; blockbuster potential unfolds

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

AbbVie partnership signals a new era for Glenmark Pharma (GNP) GNP’s subsidiary, Ichnos Glenmark Innovation (IGI), has signed an exclusive licensing agreement with AbbVie for its lead investigational asset, ISB-2001.

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

26 May 2025

2219.20

1.75%

EU and lower R&D spending drive 4Q earnings

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted a marginally lower-than-expected operating performance in 4QFY25 (2%/5% miss on revenue/EBITDA). Elevated interest outgo and lower other income led to a 16% miss on earnings.

Glenmark Pharmaceuticals Ltd. high volume past week with price gain of 21.24.

Glenmark Pharmaceuticals Ltd.

24 Dec 2024

2219.20

1.75%

GLENMARK PHARMACEUTICALS

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

19 Dec 2024

2219.20

1.75%

Company Update:Glenmark Pharma.

Not Rated: Glenmark Pharmaceuticals Ltd.

Axis Direct

As the stock is not under our coverage, we do not offer a valuation. However, Glenmark pharmaceuticals is trading at 18x FY27 PE (Bloomberg Estimates).

Glenmark Pharmaceuticals Ltd. high volume past week with price gain of 21.24.

Glenmark Pharmaceuticals Ltd.

19 Dec 2024

2219.20

1.75%

Company Update:Glenmark Pharma.

Not Rated: Glenmark Pharmaceuticals Ltd.

Axis Direct

As the stock is not under our coverage, we do not offer a valuation. However, Glenmark pharmaceuticals is trading at 18x FY27 PE (Bloomberg Estimates).

Glenmark Pharmaceuticals Ltd. has gained 61.03% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

16 Aug 2024

2219.20

1.75%

Operationally in-line 1Q; DF/EU drive earnings

Buy: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Motilal Oswal

Glenmark Pharma (GNP) delivered an in-line operating performance in 1QFY25. It witnessed robust traction in the domestic formulation (DF) and Europe businesses.

Glenmark Pharmaceuticals Ltd. has gained 48.25% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

16 Aug 2024

2219.20

1.75%

India traction improving; co maintains FY25 guidance

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) Q1FY25 result was driven by better traction in India (+12% YoY) and EU (+21%) and lower R&D (-190bps).

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

18 Jun 2024

2219.20

1.75%

GLENMARK PHARMACEUTICALS

Hold: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Deven Choksey released a Buy report for Glenmark Pharmaceuticals Ltd. with a price target of 1650.0 on 11 Jul, 2025.

Glenmark Pharmaceuticals Ltd.

27 May 2024

2219.20

1.75%

Operating performance above est.; FY25 outlook better

Neutral: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

pairment of INR23b
? Glenmark Pharma (GNP) posted lower-than-expected revenue in 4QFY24.
However, it delivered better-than-expected profitability for the quarter,
aided by an improved product mix and lower raw material costs. Having said
this, GNP has taken a considerable impairment charge on manufacturing
facilities and certain intangibles (~INR32b) during the quarter

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Is Glenmark Pharmaceuticals Ltd. worth buying?

568 Votes:

Buy 79.23%

Sell 13.73%

Hold 7.04%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf